PF-Atlas › Clinical Trials › NCT03500263

Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

PTI-808 · Phase 1

Registry ID

NCT03500263

Phase

Phase 1

Status

Completed

Drug / intervention

PTI-808

Sponsor

Proteostasis Therapeutics, Inc.

Start

2018-01-30

About this trial

PTI-808 is evaluated in NCT03500263, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Proteostasis Therapeutics, Inc.. Current status: Completed.

View NCT03500263 on ClinicalTrials.gov →

Explore related

All PTI-808 trials All IPF trials

Related trials

PTI-808 — NCT03251092

Medical disclaimer. This page summarizes public trial data for NCT03500263 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.